Clinical Trials Logo

Filter by:
NCT ID: NCT05998941 Withdrawn - Cervical Cancer Clinical Trials

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

Start date: August 2023
Phase: Phase 2
Study type: Interventional

This study used a single-arm, open phase II multicenter trial design. All eligible subjects received TQB2868 plus platinum-based chemotherapy with or without bevacizumab. A total of 39 subjects will be enrolled.

NCT ID: NCT05998928 Recruiting - Multiple Myeloma Clinical Trials

A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy

Start date: July 27, 2023
Phase: Phase 2
Study type: Interventional

This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of bispecific BCMA-GPRC5D Chimeric antigen receptor (CAR) T-cells in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy.

NCT ID: NCT05998915 Recruiting - Clinical trials for Human Microecology;Colorectal Disease;Auxiliary Diagnosis

A Multi-center Study on Human Microecology Assisted Diagnosis of Colorectal Cancer

Start date: March 1, 2023
Phase:
Study type: Observational

As for this research,we want to find whether the intestinal microecology (flora, peptidoglycan fragments) have certain distribution characteristics in colorectal diseases; whether it can predict the development of disease/as a prognostic indicator.

NCT ID: NCT05998902 Recruiting - Dysphagia Clinical Trials

Optimizing Early Nutrition Support in Severe Stroke-2

Start date: December 20, 2023
Phase: Phase 3
Study type: Interventional

Post stroke pneumonia (PSP) is one of the common early complications of stroke. Post-stroke infections, in general, are associated with less favorable neurologic outcomes. Aspiration is one of the most feared complications of enteral nutrition and can lead to the occurrence of pneumonia. Severe stroke patients are at high risk for aspiration due to some factors such as the reduced level of consciousness, inability to protect the airway and so on. The purpose of this study is to explore the ideal nutrition support strategy for patient with acute severe stroke to help reduce the incidence of PSP and improve the prognosis.

NCT ID: NCT05998759 Not yet recruiting - Thrombocytopenia Clinical Trials

Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Start date: October 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy and safety of Telitacicept for the treatment of connective tissue disease-associated thrombocytopenia.

NCT ID: NCT05998733 Recruiting - Sepsis Clinical Trials

The Impact of Coagulation Disorders on the Diagnosis and Prognosis of Sepsis

Start date: June 1, 2022
Phase:
Study type: Observational

The study was a retrospective, single-center clinical study. From all patients admitted to the emergency ICU during the period of 2013.1.1-2019.12.31, the investigators screened all patients who met the criteria of 1) ≤7 days from symptom onset to enrollment; 2) patients who also met the criteria of the presence of clinical infections and Sequential Organ Failure Assessment (SOFA) score ≥2; and 3) met the exclusion criteria, and retrospectively collected coagulation indices of the patients before anticoagulation with or without the use of heparin or low molecular heparin, and recorded the worst values of coagulation function of patients before heparin were recorded, and the organ function, inflammatory response, immune indexes, and conversion rate of severe disease were observed, so as to investigate the role of conventional coagulation indexes (FDP, D-dimer) and thromboelastography in the early diagnosis of septicemia patients and to indicate the prognosis.

NCT ID: NCT05998720 Recruiting - Hip Disease Clinical Trials

Application of New Magnetic Resonance UTE Technique in Hip Joint Lesions

Start date: July 1, 2023
Phase:
Study type: Observational [Patient Registry]

Explore the imaging and quantitative monitoring of hip bone, cartilage and ligament by magnetic resonance UTE technology, combined with QCT and DXA technology, to provide a more accurate basis for clinical evaluation and treatment.

NCT ID: NCT05998707 Recruiting - Lung Diseases Clinical Trials

The Application of the New Magnetic Resonance UTE Technique in Thoracic Lesions

Start date: July 1, 2023
Phase:
Study type: Observational [Patient Registry]

Quantitative characteristic values of lung lesions were obtained by UTE technique, so as to make qualitative diagnosis of benign and malignant lesions. And to explore the clinical feasibility of CT-like technology - high resolution ZTE technology in the diagnosis of pulmonary diseases.

NCT ID: NCT05998421 Completed - Acupuncture Clinical Trials

The Effects of Acupuncture on the Natural Pregnancy in Patients With Recurrent Abortion

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Recurrent spontaneous abortion (RSA) is a common pregnancy complication in women of reproductive age and the cause of RSA remains largely unclear. Acupuncture is widely used in clinical practice to treat infertility and abortion. The role of acupuncture in the treatment of infertility is still unclear. The investigators conducted a randomized, prospective, controlled clinical trial to investigate its potential impact on pregnancy outcome. Herein, the investigators not only evaluated the changes in patients' psychological stress before and after treatment but also followed up on pregnancy outcomes. In addition, changes in uterine artery blood flow were observed by ultrasound. Changes in coagulation-related indicators were also detected.

NCT ID: NCT05998304 Completed - Clinical trials for Healthy Male Subjects

ADME Study of [14C] Yiqibuvir in Healthy Male Subjects

Start date: August 7, 2023
Phase: Phase 1
Study type: Interventional

This is a single-centre, open-label, mass balance and biotransformation study in healthy male subjects utilising a single oral dose of [14C] Yiqibuvir.